<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02266966</url>
  </required_header>
  <id_info>
    <org_study_id>F02695LP105</org_study_id>
    <nct_id>NCT02266966</nct_id>
  </id_info>
  <brief_title>Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Medicament</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Medicament</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this functional Magnetic Resonance Imaging (MRI) study is to assess the effect of
      single dose of F2695 at 75mg on modulation of the cerebral motor network.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor system cortical areas activation magnitude during a paced motor task.</measure>
    <time_frame>1 day (Period 1/Day +1, Period 2/Day +8)</time_frame>
    <description>Location coordinates (x,y,z),
Voxel cluster size expressed in terms number of voxels,
Intensity as measured with a Z-score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) as a measure of safety and tolerability</measure>
    <time_frame>up to 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Subject</condition>
  <arm_group>
    <arm_group_label>F2695</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose - 2 capsules / Day on Day 1 and Day 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose - 2 capsules / Day on Day 1 and Day 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F2695</intervention_name>
    <arm_group_label>F2695</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Male right-handed*, healthy volunteers 18 to 40 years of age. Having signed and dated an
        informed consent form

        Exclusion Criteria:

        Any significant disease or history of any clinically important drug allergy. Acute disease
        state within 7 days. History of drug abuse within 1 year. History or current excessive use
        of alcohol and / or positive alcohol screen. History of narrow angle glaucoma, seizures or
        epilepsy or brain injury. History of Gluten sensitivity, Gluten intolerance (celiac
        disease), Wheat allergy or Wheat intolerance.

        History of obstructive voiding symptoms, including urinary retention.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François Chollet</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Purpan CHU TOULOUSE, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique (CIC)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2014</study_first_submitted>
  <study_first_submitted_qc>October 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2014</study_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

